Search
-
After Final Presidential Debate, Undecideds Favor Obama - Obama 53%, McCain 47%
McCain's Performance Rated As Much-Improved (53% Better than other debates), But Obama Still Seen As Debate Winner (56% Obama / 44% McCain)
Undecided voters perceive Obama as stronger on key issues -- change (Obama 67%/McCain 33%), helping the middle class (Obama 69%/McCain 31%), healthcare (Obama 67%/McCain 33%) and creating jobs (Obama 62%/McCain 38%) -
Obama Widens Lead in Presidential Race- Obama 48%, McCain 39%
McCain Seen As More Negative Campaigner - McCain 53%, Obama 30%; More Than Half Report Negative Campaigning is Not Effective (39% Effective; 57% Not Effective)
Health Care (32%), Energy (31%) Trump Defense as Key Funding Priorities for Next President -
The Ipsos Weekly College Football Fan First Poll
Alabama STILL #1 Among College Football Fans This Week
-
After Second Presidential Debate, Undecideds Move Toward Obama - Obama 57%, McCain 43%
Nearly Two Thirds (61%) Think Obama Performed Better in Town Hall Debate
Undecided voters perceive Obama as stronger on key issues -- change (Obama 69%/McCain 31%), helping the middle class (Obama 73%/McCain 27%) and creating jobs (Obama 63%/McCain 37%) -
Amazon and Rhapsody Show Strong Gains in Digital Music Market While iTunes Remains Dominant
5th Annual TEMPO Digital Music Brandscape Study From Ipsos Reveals Emerging Changes Within The Category
Shifts Come At Expense Of Lesser-Known Brands, Further Market Consolidation Likely In The Near Future -
Financial Meltdown has Effect
Obama opens 15-point lead on the Economy
Obama 52%, McCain 37%
Economy jumps 6 points as most important issue
Obama Opens 7-Point Lead in Presidential Race -
Obama 47%, McCain 40% -
Obama Opens 4-Point Lead in Presidential Race - Obama 46%, McCain 42%
Confidence in Security of Bank Assets Remains High After Wall Street Meltdown
But Voters See the Need For More Regulation - 55%, Not Enough Regulation of Banking -
Snyderman Deepens Client Perspective at Ipsos Health
Expert Health Research Specialist Moves to the Agency Side from Merck